Gabriel Tremblay

ORCID

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 10

Top Venues

Future oncology (London, England)

BMC cancer

PharmacoEconomics

Journal of comparative effectiveness research

This page only lists publications with an associated author ORCID identifier.

Publications

Patrick Daniele, Carla Mamolo, Joseph C Cappelleri, Timothy Bell, Alexander Neuhof, Gabriel Tremblay, Mihaela Musat, Anna Forsythe
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma. Future oncology (London, England) 19 (6) (2023)
Patrick Daniele, Carla Mamolo, Joseph C Cappelleri, Timothy Bell, Alexander Neuhof, Gabriel Tremblay, Mihaela Musat, Anna Forsythe
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma. Future oncology (London, England) (2023)
Patrick Daniele, Carla Mamolo, Joseph C Cappelleri, Timothy Bell, Alexander Neuhof, Gabriel Tremblay, Mihaela Musat, Anna Forsythe
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma. Future oncology (London, England) 19 (6) (2023)
Patrick Daniele, Carla Mamolo, Joseph C Cappelleri, Timothy Bell, Alexander Neuhof, Gabriel Tremblay, Mihaela Musat, Anna Forsythe
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma. Future oncology (London, England) (2023)
Gabriel Tremblay, Michael Groff, Laura Iadeluca, Patrick Daniele, Keith Wilner, Robin Wiltshire, Lauren Bartolome, Tiziana Usari, Joseph C Cappelleri, D Ross Camidge
Effectiveness of crizotinib versus entrectinib in ROS1 -positive non-small-cell lung cancer using clinical and real-world data. Future oncology (London, England) 18 (17) (2022)
Lauren Ramjee, William Lemay, Nesrin Vurgun, Nathalie Charland, Chris T Bauch, Gokul Raj Pullagura, Sherilyn K D Houle, Gabriel Tremblay
Projected impact of a plant-derived vaccine on the burden of seasonal influenza in Canada. Human vaccines & immunotherapeutics 17 (10) (2021)
Jatin Shah, Sharon Shacham, Michael Kauffman, Patrick Daniele, Dimitrios Tomaras, Gabriel Tremblay, Rene-Olivier Casasnovas, Marie Maerevoet, Josee Zijlstra, George Follows, Joost S P Vermaat, Nagesh Kalakonda, Andre Henri Goy, Sylvain Choquet, Eric Van Den Neste, Brian T Hill, Catherine Thieblemont, Federica Cavallo, Fátima de la Cruz, John Kuruvilla, Nada Hamad, Reda Bouabdallah, Ulrich Jäger, Paolo Caimi, Ronit Gurion, Krzysztof Warzocha, Sameer Bakhshi, Juan Manuel Sancho, Michael Schuster, Miklós Egyed, Fritz Offner, Theodoros P Vasilakopoulos, Priyanka Samal, Agnes Nagy, Matthew Ku, Miguel Ángel Canales Albendea
Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma. Future oncology (London, England) 17 (11) (2021)
Gabriel Tremblay, Patrick Daniele, Janis Breeze, Lingling Li, Jatin Shah, Sharon Shacham, Michael Kauffman, Monika Engelhardt, Ajaj Chari, Ajay Nooka, Dan Vogl, Maria Gavriatopoulou, Meletios-Athanasios Dimopoulos, Paul Richardson, Noa Biran, David Siegel, Philip Vlummens, Chantal Doyen, Thierry Facon, Mohamad Mohty, Nathalie Meuleman, Moshe Levy, Luciano Costa, James E Hoffman, Michel Delforge, David Kaminetzky, Katja Weisel, Marc Raab, David Dingli, Sascha Tuchman, Frenzel Laurent, Ravi Vij, Gary Schiller, Philippe Moreau, Joshua Richter, Martin Schreder, Klaus Podar, Terri Parker, Robert Frank Cornell, Karlin Lionel, Sylvain Choquet, Jagannath Sundar
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study. BMC cancer 21 (1) (2021)
Michael Dolph, Gabriel Tremblay, Hoyee Leong
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial. PharmacoEconomics 39 (11) (2021)
Gabriel Tremblay, Patrick Daniele, Timothy Bell, Geoffrey Chan, Andrew Brown, Joseph Christopher Cappelleri
Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia. Journal of comparative effectiveness research 10 (7) (2021)

Gabriel Tremblay.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Gabriel Tremblay